CytomX appoints Zhen Su to Board; adopts amended bylaws for stockholder proposals
CytomX Therapeutics, Inc.
Zhen Su, M.D., M.B.A., appointed to Board as Class I director effective March 20, 2024, filling a vacancy.
Dr. Su receives standard non-employee director compensation and an option to purchase 76,000 shares vesting over three years.
Board adopted Amended and Restated Bylaws to modernize stockholder nomination and proposal procedures, including removal of 'acting in concert' provisions.
Bylaw amendments effective immediately with clarifying and technical changes.
On March 20, 2024, Zhen Su, M.D., M.B.A., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective March 20, 2024, as a Class I director, with an initial term expiring at the Company’s 2025 annual meeting of stockholders, filling a vacancy.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Zhen Su was appointed as Class I director at CytomX Therapeutics, Inc..
Action
appointed
Role
Class I director
Exact text from the filing
On March 20, 2024, Zhen Su, M.D., M.B.A., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective March 20, 2024, as a Class I director, with an initial term expiring at the Company’s 2025 annual meeting of stockholders, filling a vacancy.
CytomX Therapeutics, Inc.: Amended and restated bylaws to modernize stockholder nomination and proposal procedures, remove 'acting in concert' provisions, and make clarifying changes (effective 2024-03-20).
Change
bylaw amendment
Effective
2024-03-20
Exact text from the filing
On March 20, 2024, the Board unanimously adopted Amended and Restated Bylaws of the Company (the bylaws, as so amended and restated, the “Amended and Restated Bylaws”), effective immediately, to, among other things, modernize and enhance certain disclosure and procedural requirements related to stockholder nominations of directors and submissions of stockholder proposals regarding other business at stockholder meetings, including removing the “acting in concert” provisions previously contained in the Company’s bylaws, as well as certain other clarifying, technical and conforming changes.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.